Medigene AG (XTER:MDG1)
€ 1.126 0.046 (4.26%) Market Cap: 15.92 Mil Enterprise Value: 4.44 Mil PE Ratio: 0 PB Ratio: 0.81 GF Score: 46/100

Medigene AG to Discuss TCR-T Therapy for Solid Tumors Transcript

Jun 20, 2023 / 02:00PM GMT
Release Date Price: €3.79 (-4.09%)
Operator

Hello, and welcome to the Medigene R&D event. (Operator Instructions) As a reminder, this call is being recorded and a replay will be made available on the Medigene website following the conclusion of the event. I'd now like to turn the call over to your host, Selwyn Ho, CEO of Medigene. Please go ahead, Selwyn.

Selwyn Ho
Medigene AG - CEO

Good morning. Good afternoon to all of you. My name is Selwyn Ho, and I'm the CEO of Medigene and thank you for joining us today at Medigene's R&D event where we'll be discussing Medigene's approach to the development of TCR-T therapies for solid tumors.

Here's the agenda for our event. In over approximately the next hour, members of our R&D and corporate leadership teams will be discussing a number of topics. Firstly, our focus on patients and the need in solid tumors.

Secondly, what could be the ideal adoptive cell therapy for solid tumors?

Next up would be our end-to-end platform as the basis of our approach to generate optimal TCRs and ultimately, we believe highly differentiated

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot